COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Operating Income
Profit from core operations after operating expenses, before interest and taxes.
COMPASS Pathways plcNASDAQ: CMPS
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$42.83M, compared with -$49.62M a year earlier. Trailing-twelve-month operating income was -$172.25M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -0.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$42.83M+6.8% QoQ
- Last fiscal yearDec 2025
- -$179.04M-0.5% YoY
- LTMMar 2026
- -$172.25M+9.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.7% | +100.0% | +86.3 pp |
| 1 year | -0.5% | +100.0% | +100.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (179.04M) USD
- Year-over-year change
- -0.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (179.04M) | -0.5% |
| FY2024 | 2024-12-31 | (178.21M) | -30.2% |
| FY2023 | 2023-12-31 | (136.92M) | -24.0% |
| FY2022 | 2022-12-31 | (110.4M) | -32.7% |
| FY2021 | 2021-12-31 | (83.22M) | — |
Operating Income vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 operating income of -$172.25M is the 7th highest of the 11 companies compared; the peer median is -$94.45M.
- Its year-over-year change of +9.0% is the highest of 10, against a peer median of -38.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $230.65M | +4.0% | +20.2% | 24.0% | |
| LTM Sep 2026 | $122.33M | -49.2% | — | 10.2% | |
| LTM Jun 2026 | -$35.14M | -117.4% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$46.86M | — | — | — |
| LTM Mar 2026 | -$66.69M | -29.4% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$122.21M | -31.3% | — | 611.0% |
| LTM Mar 2026 | -$172.25M | +9.0% | — | — | |
| LTM Mar 2026 | -$210.04M | -140.9% | — | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$254.15M | -68.1% | — | — |
| LTM Sep 2026 | -$406.72M | -38.8% | — | — | |
| LTM Jun 2026 | -$542.7M | -1.7% | — | 15058.2% | |
| Peer median (excluding CMPS) | -$94.45M | -38.8% | +20.2% | 317.5% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
| Selling, General & Admin | 39.19M | 45.35M | 49.4M | 59.17M | 60.6M |
| Operating Expenses | 83.22M | 110.4M | 136.92M | 178.21M | 179.04M |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| EBITDA | (71.37M) | (90.77M) | (115.24M) | (148.82M) | (285.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.22M) | (110.4M) | (136.92M) | (178.21M) | (179.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 4.62M | 8.27M | 7.18M |
| Interest Expense | 0 | 0 | 2.2M | 4.48M | 4.52M |
| Other Income / Expenses | 11.68M | 19.31M | 19.24M | 24.68M | (111.3M) |
| Income Before Tax | (71.54M) | (91.1M) | (117.68M) | (153.53M) | (290.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 199K | 408K | 780K | 1.59M | (2.47M) |
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| EPS (Diluted) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| Weighted Avg Shares | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
| Weighted Avg Shares (Diluted) | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.